Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of “Buy” by Analysts

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have received a consensus rating of “Buy” from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $10.14.

Several brokerages recently issued reports on AQST. Oppenheimer began coverage on shares of Aquestive Therapeutics in a research report on Monday, June 2nd. They issued an “outperform” rating and a $7.00 target price for the company. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a report on Thursday, May 15th. Alliance Global Partners reissued a “buy” rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Raymond James set a $7.00 target price on Aquestive Therapeutics in a research report on Friday, March 7th. Finally, Lake Street Capital reduced their price target on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, March 7th.

Aquestive Therapeutics Trading Up 3.3%

Shares of Aquestive Therapeutics stock opened at $3.42 on Friday. The company has a market capitalization of $339.70 million, a P/E ratio of -7.60 and a beta of 1.94. The stock has a fifty day simple moving average of $2.76 and a 200 day simple moving average of $3.09. Aquestive Therapeutics has a 12-month low of $2.12 and a 12-month high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The firm had revenue of $8.72 million during the quarter, compared to analysts’ expectations of $12.23 million. On average, analysts predict that Aquestive Therapeutics will post -0.46 EPS for the current year.

Institutional Investors Weigh In On Aquestive Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Everstar Asset Management LLC boosted its stake in shares of Aquestive Therapeutics by 38.7% during the first quarter. Everstar Asset Management LLC now owns 300,000 shares of the company’s stock valued at $870,000 after purchasing an additional 83,777 shares during the period. AQR Capital Management LLC lifted its holdings in Aquestive Therapeutics by 12.2% during the 1st quarter. AQR Capital Management LLC now owns 129,019 shares of the company’s stock valued at $374,000 after buying an additional 14,025 shares in the last quarter. DAFNA Capital Management LLC lifted its holdings in Aquestive Therapeutics by 11.8% during the 1st quarter. DAFNA Capital Management LLC now owns 142,000 shares of the company’s stock valued at $412,000 after buying an additional 15,000 shares in the last quarter. Stonepine Capital Management LLC boosted its position in Aquestive Therapeutics by 25.0% in the 1st quarter. Stonepine Capital Management LLC now owns 200,000 shares of the company’s stock valued at $580,000 after buying an additional 40,000 shares during the period. Finally, Walleye Capital LLC purchased a new stake in Aquestive Therapeutics in the 1st quarter valued at about $115,000. 32.45% of the stock is currently owned by hedge funds and other institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.